OSUR Stock Overview
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 0/6 |
Past Performance | 1/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
OraSure Technologies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.14 |
52 Week High | US$8.45 |
52 Week Low | US$4.38 |
Beta | 0.17 |
1 Month Change | -12.41% |
3 Month Change | -25.93% |
1 Year Change | 5.14% |
3 Year Change | -47.39% |
5 Year Change | -42.99% |
Change since IPO | 11.64% |
Recent News & Updates
Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Mar 01Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
Feb 29Recent updates
Earnings Beat: OraSure Technologies, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Mar 01Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
Feb 29OraSure Technologies, Inc.'s (NASDAQ:OSUR) Business And Shares Still Trailing The Industry
Dec 20Returns On Capital At OraSure Technologies (NASDAQ:OSUR) Have Stalled
Nov 08Industry Analysts Just Upgraded Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Forecasts By 14%
Aug 09Analysts Have Just Cut Their OraSure Technologies, Inc. (NASDAQ:OSUR) Revenue Estimates By 12%
May 16Return Trends At OraSure Technologies (NASDAQ:OSUR) Aren't Appealing
May 13Party Time: Brokers Just Made Major Increases To Their OraSure Technologies, Inc. (NASDAQ:OSUR) Earnings Forecasts
Feb 17We're Not Very Worried About OraSure Technologies' (NASDAQ:OSUR) Cash Burn Rate
Jan 16OraSure wins $8.6M government contract for next-gen Ebola test
Sep 28OraSure: Revenue Mix Continues To Present Risk
Sep 06Biden administration ending free at-home COVID tests due to lack of funding
Aug 29Is OraSure Technologies (NASDAQ:OSUR) In A Good Position To Invest In Growth?
Aug 11Are OraSure Technologies, Inc. (NASDAQ:OSUR) Investors Paying Above The Intrinsic Value?
Jun 14OraSure: Not So Sure With Softening Fundamentals, Fairly Priced At $2.54
Jun 10OraSure Technologies: A Bet On What Used To Be
Mar 05OraSure Technologies (NASDAQ:OSUR) May Have Issues Allocating Its Capital
Nov 11The Bottom Fishing Club: OraSure Technologies
Oct 22Shareholder Returns
OSUR | US Medical Equipment | US Market | |
---|---|---|---|
7D | -5.8% | 2.2% | 0.4% |
1Y | 5.1% | 13.3% | 28.8% |
Return vs Industry: OSUR underperformed the US Medical Equipment industry which returned 12% over the past year.
Return vs Market: OSUR underperformed the US Market which returned 29.5% over the past year.
Price Volatility
OSUR volatility | |
---|---|
OSUR Average Weekly Movement | 6.1% |
Medical Equipment Industry Average Movement | 7.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OSUR's share price has been volatile over the past 3 months.
Volatility Over Time: OSUR's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 638 | Carrie Eglinton Manner | https://www.orasure.com |
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services.
OraSure Technologies, Inc. Fundamentals Summary
OSUR fundamental statistics | |
---|---|
Market cap | US$453.11m |
Earnings (TTM) | US$53.66m |
Revenue (TTM) | US$405.47m |
8.4x
P/E Ratio1.1x
P/S RatioIs OSUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OSUR income statement (TTM) | |
---|---|
Revenue | US$405.47m |
Cost of Revenue | US$226.05m |
Gross Profit | US$179.42m |
Other Expenses | US$125.77m |
Earnings | US$53.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.73 |
Gross Margin | 44.25% |
Net Profit Margin | 13.23% |
Debt/Equity Ratio | 0% |
How did OSUR perform over the long term?
See historical performance and comparison